First Oncolytic Immunotherapy Improves Durable Response Rate in Melanoma

Share this content:

the Cancer Therapy Advisor take:

Talimogene laherparepvec (T-VEC) is the first oncolytic immunotherapy to demonstrate therapeutic benefit against melanoma in a phase III clinical trial, a new study published online early in the Journal of Clinical Oncology has shown.

For the study, researchers enrolled 436 patients with injectable melanoma that was not surgically resectable and randomly assigned them 2:1 to intralesional T-VEC or subcutaneous granulocyte macrophage colony-stimulating factor (GM-CSF).

Results showed that the durable response rate was 16.3% (95% CI: 12.1-20.5) and 2.1% (95% CI: 0-4.5) in the T-VEC and GM-CSF groups, respectively (OR = 8.9; P < 0.001). In addition, median overall survival was 23.3 months (95% CI: 19.5-29.6) with T-VEC and 18.9 months (95% CI: 16.0-23.7) with GM-CSF (HR = 0.79; 95% CI: 0.62-1.00; P = 0.051).

Researchers found that T-VEC was particularly effective in patients with treatment-naive disease and in patients with stage IIIB, IIIC, or IVM1a melanoma.

In regard to safety, the most common adverse events associated with T-VEC treatment were fatigue, chills, and pyrexia.

T-VEC is a herpes simplex virus type 1-derived oncolytic immunotherapy ultimately designed to enhance systemic antitumor immune response.

Talimogene laherparepvec is the first oncolytic immunotherapy to demonstrate therapeutic benefit aga
Talimogene laherparepvec is the first oncolytic immunotherapy to demonstrate therapeutic benefit against melanoma.
T-VEC was compared with GM-CSF in patients with unresected stage IIIB to IV melanoma in a randomized open-label phase III trial.
READ FULL ARTICLE From Ascopubs

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters